- Carmat announced on Tuesday (25 October) that it will resume production of the world’s most advanced total artificial heart.
- Despite Europe boasting the world’s second-largest medical technologies industry after the US with an estimated worth of around €140 billion in 2020, Carmat CEO Stéphane Plat warned EURACTIV France that Europe may not keep that position for long, as innovation is expensive and “money is hard to find in Europe”.
- Regarding the risk of slowing down health innovation, the CEO also warned that “the competent authorities are responding to public pressure that has seized the issue,” before adding that “this society is going to be a barrier to innovation”.
French CEO warns of uncertain future for Europe’s MedTech sector
